mai President Prapan Charoenprawatt said TRP will be listed and start trading on mai in the Services industry group.
TRP operates a medical clinic named "Teeraporn Clinic" to provide general people with facial plastic surgery including Face-Lock, Lucky eye (double eyelid surgery), Lucky nose (rhinoplasty) and skin treatment. The company's teams of specialists have more than ten years of experience, led by Asst. Prof. Dr. Choladhis Sinrachtanant, a former president of the Thai Academy of Facial Plastic & Reconstructive Surgery who has expertise and experience for more than 40 years. Plastic surgery generates 97 percent of the company's total revenue. Teeraporn Clinic operates in a five-story building on Charoen Nakhon Road in Klong San district, covering an area of 1,157 square meters. There are six operating rooms, three consulting rooms and 26 doctors. The company is building a plastic surgery hospital on Somdet Phrachao Taksin Road in Thon Buri district. The new facility, with investment cost of THB 922 million, will have a combined area of 9,918 square meters and it is expected to open in the fourth quarter of 2024.
TRP has a paid-up capital of THB 175 million, consisting of 260 million existing common shares and 90 million newly issued shares, with a par value of THB 0.50 each. The company offered 67.5 million newly issued shares to persons at underwriters' discretion, 13.5 million shares to its patrons and 9 million shares to its directors, executives and/or employees during October 10-12, 2023, at THB 14.00 each for a total of THB 1.26 billion in fund raised. The IPO price was equivalent to price-to-earnings ratio (P/E ratio) of 21.12 times. The earning per share is equal to THB 0.66, which was calculated from the company's net profit of THB 232 million in the past four quarters (from July 1, 2022, to June 30, 2023), divided by fully diluted shares. Capital One Partners Co., Ltd. is the financial advisor and Globlex Securities Co., Ltd. is the lead underwriter.
TRP Chief Executive Officer Asst. Prof. Dr. Choladhis Sinrachtanant said the company through its teams of experienced doctors focuses on excellent services for facial beauty. It is determined to endlessly develop surgical techniques through its accumulating surgical experience. The company supports its doctors in doing researches and attending overseas seminars as experts in surgery concerning facelift, eye surgery and rhinoplasty to gain reputation and confidence that the company's doctor team is a leader in facial surgery in Asia. The proceeds arising from the fundraising will be used to construct the hospital, procure medical instruments and equipment, repay financial institutions' loans and as working capital.
TRP's major shareholder after the IPO is the Jirayangyuen family (65.57 percent). The company's dividend policy is to pay at least 50 percent of annual net profit after corporate income tax and legal reserves
For more information on TRP, please see the company's prospectus at the Securities and Exchange Commission's website at www.sec.or.th; and for general information, please visit www.teerapornclinic.com and www.set.or.th.
Source: SET Corporate Communications